Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Health Catalyst Inc (NASDAQ: HCAT) closed at $3.3 up 1.85% from its previous closing price of $3.24. In other words, the price has increased by $1.85 from its previous closing price. On the day, 0.87 million shares were traded. HCAT stock price reached its highest trading level at $3.295 during the session, while it also had its lowest trading level at $3.13.
Ratios:
For a deeper understanding of Health Catalyst Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.48.
Cantor Fitzgerald Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 02 ’25 when Linda Llewelyn bought 2,854 shares for $3.36 per share.
Kevin Freeman bought 4,578 shares of HCAT for $15,394 on Sep 02 ’25. On Sep 02 ’25, another insider, Benjamin Landry, who serves as the Officer of the company, bought 3,138 shares for $3.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 232232880 and an Enterprise Value of 307683968. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.73 while its Price-to-Book (P/B) ratio in mrq is 0.67. Its current Enterprise Value per Revenue stands at 0.973 whereas that against EBITDA is -17.186.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.65, which has changed by -0.54732513 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $9.24, while it has fallen to a 52-week low of $2.52. The 50-Day Moving Average of the stock is -8.20%, while the 200-Day Moving Average is calculated to be -32.40%.
Shares Statistics:
For the past three months, HCAT has traded an average of 749.55K shares per day and 1024670 over the past ten days. A total of 70.27M shares are outstanding, with a floating share count of 66.78M. Insiders hold about 5.11% of the company’s shares, while institutions hold 78.48% stake in the company. Shares short for HCAT as of 1755216000 were 4903674 with a Short Ratio of 6.54, compared to 1752537600 on 3741056. Therefore, it implies a Short% of Shares Outstanding of 4903674 and a Short% of Float of 7.9399999999999995.
Earnings Estimates
Health Catalyst Inc (HCAT) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.12, with high estimates of $0.16 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.62 and $0.16 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is $0.42, with 10.0 analysts recommending between $0.62 and $0.28.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $75.02M this quarter.It ranges from a high estimate of $75.39M to a low estimate of $74.91M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $76.35MFor the next quarter, 9 analysts are estimating revenue of $74.75M. There is a high estimate of $75.26M for the next quarter, whereas the lowest estimate is $74M.
A total of 12 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $335M, while the lowest revenue estimate was $309.55M, resulting in an average revenue estimate of $314.15M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $316.12M in the next fiscal year. The high estimate is $363.7M and the low estimate is $298.22M.
